Johnson & Johnson (NYSE:JNJ) is Great West Life Assurance Co. Can’s 5th Largest Position

Great West Life Assurance Co. Can increased its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,294,564 shares of the company’s stock after acquiring an additional 1,993 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Great West Life Assurance Co. Can’s portfolio, making the stock its 5th biggest position. Great West Life Assurance Co. Can’s holdings in Johnson & Johnson were worth $538,321,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC increased its holdings in shares of Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $39,000. Cardinal Capital Management Inc. increased its holdings in shares of Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust increased its holdings in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of several analyst reports. Citigroup raised their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. StockNews.com started coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Atlantic Securities dropped their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Morgan Stanley dropped their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Finally, Barclays started coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Insider Activity

In other news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the transaction, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock valued at $40,960,735 in the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ opened at $168.74 on Monday. The stock has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock’s 50-day simple moving average is $176.14 and its two-hundred day simple moving average is $171.20. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.